The technology could set new standards for data enrichment and patient-centric conduct of clinical trials February 23, 2021 08:00 ET | Source: Notal Vision Manassas, VA, Feb. 23, 2021 (GLOBE…
Read More
NexImmune Raises Gross Proceeds of $126.5M in Upsized IPO after Full Exercise of Underwriters’ Option to Purchase Additional Shares Feb 23, 2021, 08:00 ET ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/…
GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate…
With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel immunotherapy…
BALTIMORE, MD, January 5, 2021 – AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and…
Zeldis formerly served as Celgene CMO and CEO of Celgene Global Health Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist Both will help NexImmune advance…
TUE, DEC 22, 2020 16:30 CET Cereno Scientific announced today that the agreement with Mangold Fondkommission to act as liquidity provider for the company’s share has been terminated. The share…
Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) GAITHERSBURG, Md., Dec….
NEW YORK, Nov. 19, 2019 /PRNewswire/ — 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational…
GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) — NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that an abstract containing preliminary data from its first-in-human…
